EQS-News: MediClin AG: Encouraging development of Group sales in the first quarter of 2023

Donnerstag, 04.05.2023 12:51 von DGAP - Aufrufe: 133

EQS-News: MediClin AG / Key word(s): Quarter Results MediClin AG: Encouraging development of Group sales in the first quarter of 2023 04.05.2023 / 12:51 CET/CEST The issuer is solely responsible for the content of this announcement.


Offenburg, May 4, 2022

Encouraging development of Group sales in the first quarter of 2023

 In the first three months of 2023, MEDICLIN generated Group sales of EUR 176.7 mill. Sales in the first quarter of 2022 in the amount of EUR 174.2 mill. had still included EUR 7.7 mill. in benefits under the Corona protective shield. These benefits are no longer paid since the end of the previous year. In operating terms, therefore, sales improved by EUR 9.8 mill. or 5.9 % in the first quarter of the current financial year. The Group-EBIT improved by EUR 1.0 mill. to EUR –1.7 mill. despite the higher burdens.

On the costs side, the cost of raw materials and consumables used was EUR 36.4 mill., corresponding to an increase of EUR 2.6 mill. or 7.6 % compared to the prior-year value. These cost increases were caused by higher energy costs and higher expenses for external medical staff. Staff costs climbed by EUR 4.5 mill. or 4.0 %, respectively.

Gross capital expenditure amounted to EUR 8.1 mill. in the first quarter of 2023 (Q1 2022: EUR 3.8 mill.). Cash and cash equivalents as of 31 March 2023 amounted to EUR 89.8 mill. (31.12.2022: EUR 88.0 mill.).

MEDICLIN intends to build on its strengths

MEDICLIN’s strong points are rehabilitation and interdisciplinary cooperation between acute care and rehabilitation. With regard to the rehabilitation or post-acute sector, however, the Company expects rising demand for preventive care and more extensive therapeutic post-acute care. MEDICLIN intends to actively contribute to shaping this trend with outpatient and digital solutions.

Mercurius Health acquires Robert Janker Klinik in Bonn

The Robert Janker Klinik is specialised in radiotherapy, interventional radiology and palliative care. MEDICLIN has found the right partner in Mercurius Health for the further development of the clinic, which specialises in minimally invasive diagnostics and cutting-edge oncology therapies. The Medical Care Center Bonn, which belongs to the clinic, will also be transferred. The transaction was signed on January 11, 2023, and has been completed following regulatory approvals at the current time.

Outlook

The Management Board assumes that, driven by rising demand for medical, therapeutic and nursing care services, sales and earnings will increase in 2023 − subject to material adverse changes in the economic or regulatory environment.

The interim report as of 31 March 2023 is available from today under www.mediclin.de in German and English.

 

About MEDICLIN Aktiengesellschaft (Ticker: MED; WKN: 659 510)

MEDICLIN includes 33 clinics, six care facilities and eleven medical care centers. The Group has around 8,300 beds/care places and employs around 10,000 people. In a strong network, MEDICLIN offers the patient integrative care from the first visit to the doctor through the operation and subsequent rehabilitation to outpatient aftercare. Doctors, therapists and nurses work together in a carefully coordinated manner. MEDICLIN designs the care and support of people in need of care according to their individual needs and personal needs.

 

MEDICLIN ─ a company of the Asklepios Group


04.05.2023 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.eqs-news.com


Language: English
Company: MediClin AG
Okenstraße 27
77652 Offenburg
Germany
Phone: +49 (0)781 488-326
Fax: +49 (0)781 488-184
E-mail: alexandra.muehr@mediclin.de
Internet: www.mediclin.de
ISIN: DE0006595101
WKN: 659510
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange
EQS News ID: 1624717
 
End of News EQS News Service

1624717  04.05.2023 CET/CEST

fncls.ssp?fn=show_t_gif&application_id=1624717&application_name=news&site_id=ariva
Werbung

Mehr Nachrichten kostenlos abonnieren

E-Mail-Adresse
Benachrichtigungen von ARIVA.DE
(Mit der Bestellung akzeptierst du die Datenschutzhinweise)

Hinweis: ARIVA.DE veröffentlicht in dieser Rubrik Analysen, Kolumnen und Nachrichten aus verschiedenen Quellen. Die ARIVA.DE AG ist nicht verantwortlich für Inhalte, die erkennbar von Dritten in den „News“-Bereich dieser Webseite eingestellt worden sind, und macht sich diese nicht zu Eigen. Diese Inhalte sind insbesondere durch eine entsprechende „von“-Kennzeichnung unterhalb der Artikelüberschrift und/oder durch den Link „Um den vollständigen Artikel zu lesen, klicken Sie bitte hier.“ erkennbar; verantwortlich für diese Inhalte ist allein der genannte Dritte.




Kurse

2,74
-2,84%
Mediclin Chart